GFAP and neurodegenerative disease: GFAP serves as a biomarker of reactive astrogliosis, exhibiting elevated levels in plasma and cerebrospinal fluid (CSF) in neurodegenerative diseases such as Alzheimer’s disease (AD)24,25, dementia with Lewy bodies26, frontotemporal lobar degeneration27, and PD28.